News | July 12, 2025
Briefs: Emcure Pharmaceuticals and Gland Pharma
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Subscribe To Our Newsletter & Stay Updated
